ETF Holdings Breakdown of LGND

Stock NameLigand Pharmaceuticals Incorporated
TickerLGND(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS53220K5048
LEI5493008K7TB0IKP37H79

News associated with LGND

Price T Rowe Associates Inc. MD Raises Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Price T Rowe Associates Inc. MD grew its position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 13.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,518 shares of the biotechnology company’s stock after buying an additional 1,781 […] - 2025-05-09 08:47:11
Ligand Pharmaceuticals Reiterates FY25 Outlook - Update
(RTTNews) - While reporting financial results for the first quarter on Thursday, biopharmaceutical company Ligand Pharmaceuticals, Inc. (LGND) reiterated its adjusted earnings and revenue guidance for fiscal 2025. - 2025-05-08 11:44:43
Hsbc Holdings PLC Grows Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Hsbc Holdings PLC raised its stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 19.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,764 shares of the biotechnology company’s stock after buying an additional 605 shares during the quarter. Hsbc Holdings PLC’s […] - 2025-05-08 08:22:52
Mariner LLC Invests $276,000 in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Mariner LLC acquired a new stake in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) during the 4th quarter, HoldingsChannel reports. The institutional investor acquired 2,574 shares of the biotechnology company’s stock, valued at approximately $276,000. Other large investors also recently bought and sold shares of the company. Smartleaf Asset Management LLC grew its […] - 2025-05-06 07:40:47
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Sold by Barclays PLC
Barclays PLC cut its holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 8.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 39,972 shares of the biotechnology company’s stock after selling 3,484 shares during the period. […] - 2025-04-28 07:59:05
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Holdings Lifted by Sterling Capital Management LLC
Sterling Capital Management LLC lifted its holdings in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 825.4% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 546 shares of the biotechnology company’s stock after buying an additional 487 shares during […] - 2025-04-24 09:31:07
Legal & General Group Plc Acquires 214 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Legal & General Group Plc grew its stake in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 0.4% during the fourth quarter, Holdings Channel reports. The institutional investor owned 57,838 shares of the biotechnology company’s stock after purchasing an additional 214 shares during the quarter. Legal & General Group Plc’s holdings in Ligand […] - 2025-04-21 08:08:55
Ligand Pharmaceuticals (NASDAQ:LGND) Upgraded to “Hold” at StockNews.com
Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued on Tuesday. Other equities analysts have also recently issued reports about the company. Barclays increased their price target on Ligand Pharmaceuticals from $150.00 to $160.00 and gave […] - 2025-04-17 08:04:59
Geode Capital Management LLC Buys 10,171 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Geode Capital Management LLC increased its stake in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 2.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 438,441 shares of the biotechnology company’s stock after acquiring an additional 10,171 shares during […] - 2025-04-15 08:00:52
Norges Bank Invests $4.96 Million in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Norges Bank purchased a new position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) in the 4th quarter, Holdings Channel.com reports. The firm purchased 46,290 shares of the biotechnology company’s stock, valued at approximately $4,960,000. Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Loomis […] - 2025-04-10 08:02:50
Ligand Pharmaceuticals (NASDAQ:LGND) Lowered to Sell Rating by StockNews.com
Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) was downgraded by equities researchers at StockNews.com from a “hold” rating to a “sell” rating in a note issued to investors on Monday. A number of other equities research analysts have also commented on the company. Benchmark reiterated a “buy” rating and issued a $135.00 target price on […] - 2025-04-09 05:35:02
Short Interest in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Increases By 22.4%
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Free Report) was the target of a large increase in short interest in the month of March. As of March 15th, there was short interest totalling 955,100 shares, an increase of 22.4% from the February 28th total of 780,100 shares. Currently, 5.4% of the shares of the company are […] - 2025-04-04 05:15:16
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Position Raised by Teacher Retirement System of Texas
Teacher Retirement System of Texas boosted its holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 20.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,413 shares of the biotechnology company’s stock after acquiring an additional 907 shares during the period. […] - 2025-03-31 07:28:57
Ligand Pharmaceuticals (NASDAQ:LGND) Upgraded to “Hold” at StockNews.com
StockNews.com upgraded shares of Ligand Pharmaceuticals (NASDAQ:LGND – Free Report) from a sell rating to a hold rating in a research note issued to investors on Tuesday morning. Other equities research analysts have also issued research reports about the stock. Royal Bank of Canada raised their target price on shares of Ligand Pharmaceuticals from $141.00 […] - 2025-03-19 06:32:52
Ligand Pharmaceuticals (NASDAQ:LGND) Downgraded by StockNews.com to “Sell”
StockNews.com downgraded shares of Ligand Pharmaceuticals (NASDAQ:LGND – Free Report) from a hold rating to a sell rating in a report published on Monday morning. Several other analysts also recently commented on LGND. Royal Bank of Canada raised their price objective on shares of Ligand Pharmaceuticals from $141.00 to $143.00 and gave the company an […] - 2025-03-11 05:55:01
Amalgamated Bank Has $592,000 Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Amalgamated Bank grew its stake in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 3.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,526 shares of the biotechnology company’s stock after acquiring an additional 177 shares during the period. Amalgamated […] - 2025-03-05 10:26:55
New York State Common Retirement Fund Increases Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
New York State Common Retirement Fund lifted its holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 7.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 92,418 shares of the biotechnology company’s stock after buying an additional 6,123 shares during the […] - 2025-02-26 09:36:57
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Bought by Louisiana State Employees Retirement System
Louisiana State Employees Retirement System boosted its position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 3.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 9,100 shares of the biotechnology company’s stock after buying an additional 300 shares […] - 2025-02-18 08:25:05
State of Alaska Department of Revenue Increases Stock Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
State of Alaska Department of Revenue raised its stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 3.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 10,739 shares of the biotechnology company’s stock after purchasing an additional 314 shares during the […] - 2025-02-13 08:26:58
abrdn plc Reduces Stock Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
abrdn plc cut its position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 29.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 176,760 shares of the biotechnology company’s stock after selling 72,509 shares during the quarter. abrdn […] - 2025-02-07 09:28:52

LGND institutional holdings

The following institutional investment holdings of LGND have been identified

Date ETF ISIN/Name Num Shares Book value
2025-05-08 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 11,861USD 1,215,871 -3.0%
2025-05-08 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 1,610USD 165,041 -3.0%
2025-05-08 IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc)) 22,902USD 2,347,684 -3.0%
2025-05-08 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 9,236USD 946,782
2025-05-08 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 9,236USD 946,782 -3.0%
2025-05-08 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 56USD 5,741 -3.0%
Total =54,901 USD 5,627,901
Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.